Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2013 Sep 15.
Published in final edited form as: Int J Cancer. 2012 Jan 11;131(6):1417–1422. doi: 10.1002/ijc.27390

Diabetes and Risk of Esophageal and Gastric Adenocarcinomas

Xuejuan Jiang 1, Leslie Bernstein 2, Chiu-Chen Tseng 1, Anna H Wu 1
PMCID: PMC3340473  NIHMSID: NIHMS347177  PMID: 22161620

Abstract

Diabetes has been consistently associated with an increased risk of liver, pancreas and endometrial cancer and has been implicated as a risk factor for esophageal and gastric cancers, although this association has been less well studied. We sought to determine the role of diabetes in the etiology of esophageal, gastric cardia and distal gastric adenocarcinomas. This analysis included patients with esophageal adenocarcinoma (n=209), gastric cardia adenocarcinoma (n=257) and distal gastric adenocarcinoma (n=382), and 1,309 control participants from a population-based case-control study conducted in Los Angeles County. The study included non-Hispanic whites, African Americans, Hispanics and Asian Americans. The association of diabetes with the three tumor types was estimated using polytomous logistic regression. Odds ratios (ORs) and corresponding 95% confidence intervals (CIs) were estimated. Nine percent of control participants and 13% of the case patients reported a history of diabetes. After adjustment for age, gender, race, birthplace, education, cigarette smoking status and body mass index, diabetes was associated with an increased risk of esophageal adenocarcinoma (OR, 1.48; 95% CI, 0.94–2.32; P=0.089) and distal gastric adenocarcinoma (OR, 1.47; 95% CI, 1.01–2.15; P=0.045), but was not associated with risk of gastric cardia adenocarcinoma (OR, 0.96; 95% CI, 0.59–1.55; P=0.87). However, the association between diabetes and risk of DGA was statistically significant only among patients for whom we interviewed their next-of-kin. This study further investigated the association between diabetes and adenocarcinomas of the esophagus and distal stomach.

Keywords: diabetes, esophageal adenocarcinoma, gastric adenocarcinoma, case-control study, polychotomous logistic regression

Introduction

The prevalence of diabetes has been increasing globally; rates in North America are among the highest1. In 2010, 25.6 million or 11.3% of Americans ages 20 years or older had diabetes2, with an estimated 1.9 million new cases diagnosed each year. Diabetes has been consistently associated with an increased risk of cancers of the liver, pancreas and endometrium3; however, for many other cancers, data are limited. Over 18 studies have investigated the risk of esophageal and gastric cancer in relation to history of diabetes422. However, to our knowledge, only five studies distinguished adenocarcinomas from squamous carcinoma of the esophagus 1720, 23 and only two studies18, 23 specifically evaluated risk patterns of gastric cardia cancer. In this report, we have investigated whether diabetes is associated with risk of esophageal and gastric adenocarcinoma using data from a large population-based case-control study conducted among residents of Los Angeles County24.

The association between diabetes and cancer risk may be mediated via direct effects of hyperglycemia, insulin resistance and hyperinsulinemia3 or indirectly via risk factors common to both diabetes and cancer, such as obesity, diet and tobacco smoking. In the Los Angeles case-control study, cigarette smoking24, body size24, history of reflux25 and fiber intake26 have been significantly associated with esophageal and gastric adenocarcinoma. Thus, we have also explored whether the association between diabetes and risk of esophageal and gastric adenocarcinoma is modified by age, body mass index, fiber intake, reflux symptoms and cigarette smoking.

Material and Methods

Study Population

The details of the study population and design have been described previously2432. Briefly, cases for this study were men and women, ages 30–74 years with histologically confirmed, incident esophageal adenocarcinoma (EA; International Classification of Disease for Oncology code C15.0–C15.9), gastric cardiac adenocarcinoma (GCA; International Classification of Disease for Oncology code C16.0), or distal gastric adenocarcinoma (DGA; International Classification of Disease for Oncology codes C16.1–C16.6 and C16.8–C16.9) diagnosed between 1992 and 1997. They were identified by the Los Angeles County Cancer Surveillance Program, the population-based cancer registry covering Los Angeles County, a member of the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) program, and the statewide California Cancer Registry. Control participants were subjects without a diagnosis of gastric or esophageal cancer. They were individually matched to each case patient on sex, race, age (±5 years) and neighborhood of residence. A systematic algorithm based on the address of the case patient was used to recruit control subjects25. To increase the study’s statistical power, we sought two control participants for each case patient whenever possible.

In-person interviews were conducted with participants. Next-of-kin (NOK) were interviewed when case patients were unable to be interviewed due to death or illness. Although it was not feasible to blind interviewers to case (or NOK) or control status, interviewers and study participants were not aware of the study hypotheses. Written informed consent was obtained from each study participant before interview. A total of 947 case patients were interviewed, representing 77% of the 1230 eligible patients who were approached (77% for EA, 74% for GA, and 78% for DGA). Among them, 528 were matched to one control participants and 382 to two or more control participants; 37 had no eligible control participants identified. NOK interviews accounted for 271 (66 EA, 85 GCA and 120 DGA) of the interviews with case patients. We excluded 99 case patients and 47 control subjects because of extreme caloric intake or missing data on diabetes or BMI. A total of 848 case patients (209 with EA, 257 with GCA and 382 with DGA) and 1,309 control participants were included in the current analyses.

Data collection

Cases and their matching controls were interviewed by the same interviewer in almost all instances. A reference date was defined as one year before the date of diagnosis of the case patient; this same reference date was used for each case patient’s matched control subject(s). A structured questionnaire designed specifically for this study was administered during the in-person interview, obtaining data up to the reference date. The interview queried demographic information, smoking history, lifetime use of all types of alcoholic beverages, usual diet, weight at ages 20 and 40 years and on the reference date (referred to as current weight), and height. In addition, we asked detailed questions regarding personal history of conditions of esophagus and gastrointestinal tract and other medical conditions. Specifically, participants were asked if they had diabetes diagnosed by a doctor before the reference date. If the response was yes, participants were then asked age at first diagnosis, treatment received and duration of treatment.

Statistical Analysis

Odds ratios (OR) and corresponding 95% confidence intervals (CI) were estimated. To maximize statistical power, we report results from unconditional polytomous logistic regression with adjustment for the matching variables26 including age (≤49, 50–59, 60–69, ≥70 years), sex (male/female) and race (non-Hispanic white, African American, Hispanic, Asian). Birth place (US born, non-US born), level of education (<high school, high school, some college, college graduate or higher), cigarette smoking status (never smoker, former smoker, current smoker) and body mass index (BMI) at reference age (in quartiles) were also included as covariates in the analyses. Results remained materially unchanged if we further adjusted for the duration and intensity of cigarette smoking. We previously showed26 that this approach provided more precise estimates of the ORs while the magnitude of the estimated ORs was consistent with those obtained in separate conditional logistic regression analyses that preserved the original case-control match within each cancer site. Similar results were also observed when we evaluated the effect of diabetes.

One degree of freedom likelihood ratio test was used to assess the homogeneity of diabetes’ effect by potential effect modifiers including age, BMI, fiber intake, reflux history, cigarette smoking status and respondent type. We conducted these analyses separately for each type of cancer using unconditional logistic regression.

To perform a meta-analysis 33, 34 of the studies that examined EA specifically, we identified studies by a computerized search in MEDLINE (January 1960 to June 2011) of all English language and human subject articles. The reference lists of the relevant publications were also reviewed to identify additional studies. Study-specific adjusted estimates of relative risk were obtained from the original study publications and pooled according to the DerSimonian and Laird random effects model35 to allow for variation in true associations across studies. Forest plot was prepared using the Forest Plot Viewer software version 1.00 (The National Toxicology Program, Research Triangle Park, NC). Between-study heterogeneity was tested bythe Cochran’s Q test36 for statistical significance and quantified by I2, which was estimated using the equation:

I2=QdegreeoffreedomQ×100%.

All reported test significance levels (P values) are two-sided. Meta-analysis was performed using STATA 11 (StataCorp, College Station, Texas) and all other analyses were performed using the SAS 9.2 statistical software (SAS Institute Inc., Cary, NC).

Results

Characteristics of the study participants have been described in details previously25, 32. Diabetes was diagnosed in 9% of control participants and 13% of case patients. As shown in Table 1, the prevalence of diabetes among control participants increased with age (P trend=0.018), BMI (P trend<0.001) and fiber intake (P trend=0.035). Diabetes among controls was more prevalent among Hispanics and African Americans than non-Hispanic whites, although the differences by race were not statistically significant (P=0.25). The prevalence of diabetes also did not differ by sex (P=0.14) or cigarette smoking status (P=0.69).

Table 1.

Prevalence of diabetes by demographic and lifestyle characteristics among control subjects

N (row percent) Diabetes
P1
No Yes
Age
 ≤49 262 (95%) 15 (5%) 0.018
 50–59 305 (92%) 28 (8%)
 60–69 409 (91%) 41 (9%)
 ≥70 221 (89%) 28 (11%)
Sex
 Male 883 (91%) 90 (9%) 0.14
 Female 314 (93%) 22 (7%)
Race
 Non-Hispanic white 761 (92%) 64 (8%) 0.25
 African American 75 (86%) 12 (14%)
 Hispanics 257 (90%) 27 (10%)
 Asian American 104 (92%) 9 (8%)
BMI2
 Q1 365 (96%) 15 (4%) <0.001
 Q2 307 (93%) 24 (7%)
 Q3 269 (89%) 32 (11%)
 Q4 256 (86%) 41 (14%)
Fiber intake density3
 Q1 306 (93%) 24 (7%) 0.035
 Q2 309 (94%) 19 (6%)
 Q3 292 (89%) 35 (11%)
 Q4 290 (90%) 34 (10%)
Reflux symptoms
 No 1036 (92%) 91 (8%) 0.15
 Yes 161 (88%) 21 (12%)
Cigarette smoking status
 Never smokers 479 (92%) 39 (8%) 0.69
 Former smokers 518 (90%) 57 (10%)
 Current smokers 200 (63%) 16 (7%)

Abbreviations: BMI, body mass index.

1

χ2 test for race and Mantel-Haenszel χ2 test for other variables.

2

Quartile cut points for current BMI are ≤23, >23–25, >25-≤28, >28 in males, and ≤22, >22–25, >25-≤28.25, >28.25 in females.

3

Quartile cut points for total fiber intake are ≤8.9, >8.9–11,>11–14.5,>14.5 gm/day in males, and are ≤10.9, >10.9–13,>13–16.7,>16.7 gm/day in females.

Diabetes was statistically significantly associated with an increased risk of DGA in a model that adjusted for age, sex, race, smoking status and BMI (OR, 1.47; 95% CI, 1.01–2.15). A similar pattern was observed for EA (OR, 1.48; 95% CI 0.94–2.32), although this finding was only marginally statistically significant (Table 2). No association was observed between diabetes and GCA. We also investigated the time interval between the diagnosis of diabetes and the diagnosis of the patient’s cancer (for control participants, the date of diagnosis of their matched case was used). Diabetes that had been diagnosed less than 10 years before these dates was associated with an elevated risk for all three tumor types; this finding was statistically significant for DGA (P=0.028). Diabetes that had been diagnosed more than 10 years before these dates was not associated with an increased risk of any tumor type.

Table 2.

Adjusted odds ratios (and 95% confidence intervals) for esophageal and gastric adenocarcinoma in relation to diabetes.

Controls EA
GCA
DGA
Cases OR (95% CI)1 P1 Cases OR (95% CI)1 P1 Cases OR (95% CI)1 P1
No diabetes 1197 178 1.00 (ref) 233 1.00 (ref) 327 1.00 (ref)
Diabetes 112 31 1.48 (0.94–2.32) 0.089 24 0.96 (0.59–1.55) 0.87 55 1.47 (1.01–2.15) 0.045
Duration of diabetes
 ≤2 years 17 6 1.69 (0.62–4.55) 0.30 6 1.42 (0.54–3.77) 0.48 9 1.78 (0.74–4.30) 0.20
 >2–10 yrs 37 13 1.82 (0.92–3.61) 0.084 12 1.42 (0.71–2.82) 0.32 25 1.89 (1.07–3.34) 0.028
 >10 yrs 58 12 1.19 (0.61–2.33) 0.61 6 0.50 (0.21–1.18) 0.12 21 1.11 (0.63–1.94) 0.72

Abbreviations: EA, esophageal adenocarcinoma; GCA, gastric cardia adenocarcinoma; DGA, distal gastric adenocarcinoma; OR, odds ratio; CI, confidence interval; NOK, next of kin.

1

Results were estimated from multivariate unconditional polytomous logistic regression, with adjustment for age, sex, race, education, birth place, cigarette smoking status and body mass index.

Table 3 presents the stratified analyses of diabetes’s effect by age, BMI, fiber intake, reflux symptoms, cigarette smoking and respondent type. The diabetes-EA or diabetes-DGA association was more pronounced among older participants, NOK respondents, those with a low BMI (<25 kg/m2), and those without a prior history of reflux but these results were not statistically significantly different. However, the association between diabetes and risk of DGA was statistically significant only among patients for whom we interviewed NOK.

Table 3.

Adjusted odds ratios (and 95% confidence intervals) for esophageal and gastric adenocarcinoma in relation to diabetes by subgroups of interest. Numbers of cases and controls shown are those with a positive history of diabetes.

Subgroup Controls EA
GCA
DGA
Cases OR (95% CI)1 P1 Cases OR (95% CI)1 P1 Cases OR (95% CI)1 P1
Age ≤60 45 14 1.38 (0.74–2.56) 0.31 9 1.04 (0.55–1.93) 0.91 16 1.41 (0.83–2.39) 0.20
Age >60 67 17 1.54 (0.93–2.56) 0.094 15 0.91 (0.53–1.58) 0.75 39 1.51 (0.98–2.32) 0.061
P heterogeneity 0.30 0.85 0.48
BMI ≤25 39 13 2.62 (1.30–5.27) 0.007 8 1.04 (0.47–2.32) 0.92 24 1.72 (0.97–3.07) 0.065
BMI >25 73 18 1.05 (0.59–1.89) 0.87 16 0.91 (0.50–1.65) 0.74 31 1.32 (0.80–2.17) 0.28
P heterogeneity 0.058 0.78 0.71
Fiber intake ≤ median2 43 16 1.30 (0.69–2.47) 0.42 15 1.14 (0.60–2.17) 0.68 25 1.59 (0.89–2.81) 0.11
Fiber intake > median2 69 15 1.99 (1.04–3.81) 0.037 9 0.83 (0.39–1.74) 0.61 30 1.42 (0.86–2.35) 0.17
P heterogeneity 0.19 0.54 0.78
Negative reflux history 91 18 1.55 (0.88–2.75) 0.13 15 0.87 (0.48–1.56) 0.64 46 1.56 (1.03–2.36) 0.036
Positive reflux history 21 13 1.04 (0.48–2.25) 0.93 9 0.96 (0.41–2.25) 0.92 9 1.04 (0.41–2.63) 0.94
P heterogeneity 0.52 0.90 0.49
Never smokers 39 7 1.88 (0.77–4.59) 0.17 6 1.03 (0.41–2.57) 0.95 19 1.39 (0.73–2.65) 0.32
Smokers 73 24 1.38 (0.82–2.32) 0.22 18 0.93 (0.53–1.63) 0.81 36 1.51 (0.95–2.40) 0.081
P heterogeneity 0.64 0.84 0.85
Self-respondent cancer participants 112 19 1.17 (0.67–2.02) 0.58 16 0.88 (0.50–1.56) 0.67 30 1.03 (0.65–1.63) 0.91
NOK respondents for cancer patients 112 12 2.29 (1.14–4.60) 0.019 8 1.13 (0.52–2.48) 0.76 25 3.37 (1.96–5.79) <0.001
P heterogeneity 0.35 0.90 0.0007

Abbreviations: EA, esophageal adenocarcinoma; GCA, gastric cardia adenocarcinoma; DGA, distal gastric adenocarcinoma; OR, odds ratio; CI, confidence interval; NOK, next of kin; BMI, body mass index.

1

Results were estimated from multivariate unconditional polytomous logistic regression, with adjustment for age, sex, race, education, birth place, cigarette smoking status and BMI.

2

Median for total fiber intake is 11 gm/day in males and 13 gm/day in females.

Discussion

Results from this population-based case-control study from Los Angeles County provide further support that diabetes may be associated with an increased the risk of EA and DGA.

A history of diabetes was reported by 9% of our control subjects, a rate comparable with published figures in the US37. Consistent with previous reports2, 38, we also found higher prevalence rates of diabetes among control participants who were Hispanic or African American and those with higher BMI, lending further support to the reliability of our exposure assessment by self-report. The observation of a higher level of fiber intake among diabetic control participants is not surprising since these individuals may have changed their dietary habits to improve glucose tolerance after the diagnosis of diabetes.

Four case-control studies1720 and one prospective cohort study23 have investigated the diabetes-EA association (Supplemental Table 1). Three of the five studies showed a positive association; this included females in England and Scotland17 (OR, 7.00; 95% CI, 0.86–56.89), veterans in Portland, US20 (OR, 2.78; 95% CI, 1.38–5.62), and men and women in Australia18 (OR, 1.32; 95 CI, 0.85–2.05). No association was found in the NIH-AARP Diet and Health study (HR, 0.90; 95% CI, 0.67–1.20)23. Similarly, no association was found when distal EA was examined in combination with GCA among 10,465 veterans with GERD identified within the US Veterans Affairs National Patient Care Datasets (OR, 1.1; 95% CI, 0.8–1.5)19. Limitations of these studies include small sample sizes17, 20, non-population-based19, 20, use of medical records for exposure assessment19, 20 and lack of information on the duration of diabetes17, 19, 20, 23. A random-effects meta-analysis33, 34 of the four prior studies17, 18, 20, 23 that examined EA specifically as well as our result on EA risk produced a combined OR of 1.48 (95% CI, 0.96–2.28; P= 0.077; test for heterogeneity: P = 0.011, I2=69%). Supplemental Figure 1 shows the forest plot for this meta-analysis.

Although over 13 studies 416, 22 have investigated the association between gastric cancer and diabetes, only few 18, 19, 23 have evaluated this by gastric cancer subtype (Supplemental Table 1). Rubenstein et al.19 examined GCA in combination with distal EA and did not find any evidence of an association with diabetes. Neale et al.18 observed that individuals with GCA were more likely than controls to report a history of diabetes and the association was stronger for diabetes that had been diagnosed >10 years (OR, 2.16; 95% CI, 1.16–4.04). Using data from the NIH-AARP Diet and Health study, Lin et al.23 recently reported a significant association between diabetes and risk of GCA, but no significant association of diabetes with risk of gastric noncardia adenocarcinoma. Contrary to Lin et al., in the present study, we did not find any association between GCA and diabetes; however, an increased risk of DGA was observed among those with diabetes. The inconsistency observed among the current limited data highlights the need for additional research on diabetes, including information on age at diagnosis and treatment for diabetes.

Several mechanisms have been proposed to explain associations between diabetes and cancer. Metabolic abnormalities associated with diabetes, such as insulin resistance, compensatory hyperinsulinemia, the elevated levels of bioactive insulin-like growth factor and/or chronic inflammation, can stimulate cancer cell mitogenesis, proliferation, invasion and metastasis, therefore enhance the promotion and progression of cancer cells3. Hyperinsulinemia has been shown to increase bioavailable estrogen and testosterone39, sex hormones which have been suggested to play a role in the development of EA and GCA40. In addition, early evidence suggests that some diabetes treatments may also affect cancer risk3. Specific to the esophagus and stomach, it has also been reported that diabetic patients frequently suffer from delayed gastric emptying 41, which has been associated with an increased risk of reflux symptoms42, a known risk factor for esophageal cancer in the current and previous studies25. In our study, the diabetes-EA/DGA associations were more pronounced among participants without a prior history of reflux, suggesting that delayed gastric emptying is unlikely to explain our observation. It is also possible that the associations between diabetes and cancer are not causal, instead may be due to shared common risk factors such as aging and obesity. We controlled for a number of known risk factors including age, BMI and cigarette smoking in our analyses; further, the associations we observed between diabetes and EA and GCA did not differ by age and appeared to be more pronounced among subjects with low BMI (<25). Therefore, it is unlikely that the effect of diabetes was mediated by these shared risk factors.

Our study represents one of the few large population-based studies that have investigated the role of diabetes in the etiology of adenocarcinoma of the esophagus and stomach. However, our study has a number of limitations that warrant consideration in interpreting the results. Information on diabetes were based on self-report, although we considered only physician-diagnosed disease and asked extensive questions regarding diabetes (e.g. age at diagnosis, treatment). Another limitation is the relatively small number of individuals with diabetes, particularly in the subgroup analyses, increasing the likelihood of spurious associations. Despite the significant association between diabetes and DGA, our analysis did not reveal a trend toward increasing cancer risk among individuals with longer duration of diabetes. Also, our observed association between diabetes and DGA was more pronounced when restricted to patients for whom we interviewed their NOK. This may be because these patients were more susceptible to diabetes-induced complications. As individuals with diabetes are at a higher risk of cardiovascular diseases and mortality43, these susceptible individuals were also more likely to be ill or deceased and consequently participate in the study through next-of-kin interviews. This was supported by the higher rate of next-of-kin interview among diabetic cases (41%) than that among non-diabetic cases (26%) in our study.

In summary, our data suggest that diabetes may be associated with an increased risk of EA and DGA. Future studies with larger sample sizes are needed to confirm our findings, further examine timing of diabetes (age at diagnosis of diabetes, interval between age at diagnosis of diabetes and cancer), and explore possible mechanisms by which diabetes may increase the risk of these tumor types.

Supplementary Material

Supp Fig S1
Supp Table S1

Novelty and impact.

This population-based study further examined the relationship between diabetes and adenocarcinoma of the esophagus and stomach. This investigation represents one of the few studies that distinguished adenocarcinoma from squamous carcinoma of the esophagus and specifically evaluated risk patterns of gastric cardia cancer.

Acknowledgments

We thank all the study participants and the data collection team. Supported by grant no. 3RT-0122 and 10RT-0251 from the California Tobacco Related Research Program, and grant no. CA59636 from the National Cancer Institute, and NIEHS Grant # 5P30 ES07048. Incident cancer cases for this study were collected by the USC Cancer Surveillance Program (CSP), which is supported under subcontract by the California Department of Health. The CSP is also part of the National Cancer Institute’s Division of Cancer Prevention and Control Surveillance, Epidemiology, and End Results Program, under contract number N01CN25403.

Abbreviations

BMI

body mass index

CI

confidence interval

DGA

distal gastric adenocarcinoma

EA

esophageal adenocarcinoma

GCA

gastric cardia adenocarcinoma

NOK

next of kin

OR

odds ratio

SEER

Surveillance, Epidemiology, and End Results program

Footnotes

The authors have no potential conflicts of interest to disclose.

References

  • 1.International Diabetes Federation. IDF diabetes Atlas. 4. Brussels, Belgium: 2009. [Google Scholar]
  • 2.Centers for Disease Control and Prevention. National Diabetes Fact Sheet. Atlanta, Georgia: 2011. [Google Scholar]
  • 3.Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D. Diabetes and cancer: a consensus report. Diabetes Care. 2010;33:1674–85. doi: 10.2337/dc10-0666. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Adami HO, McLaughlin J, Ekbom A, Berne C, Silverman D, Hacker D, Persson I. Cancer risk in patients with diabetes mellitus. Cancer Causes Control. 1991;2:307–14. doi: 10.1007/BF00051670. [DOI] [PubMed] [Google Scholar]
  • 5.Inoue M, Iwasaki M, Otani T, Sasazuki S, Noda M, Tsugane S. Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Arch Intern Med. 2006;166:1871–7. doi: 10.1001/archinte.166.17.1871. [DOI] [PubMed] [Google Scholar]
  • 6.Kuriki K, Hirose K, Tajima K. Diabetes and cancer risk for all and specific sites among Japanese men and women. Eur J Cancer Prev. 2007;16:83–9. doi: 10.1097/01.cej.0000228404.37858.40. [DOI] [PubMed] [Google Scholar]
  • 7.La Vecchia C, Negri E, Franceschi S, D’Avanzo B, Boyle P. A case-control study of diabetes mellitus and cancer risk. Br J Cancer. 1994;70:950–3. doi: 10.1038/bjc.1994.427. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Rousseau MC, Parent ME, Pollak MN, Siemiatycki J. Diabetes mellitus and cancer risk in a population-based case-control study among men from Montreal, Canada. Int J Cancer. 2006;118:2105–9. doi: 10.1002/ijc.21600. [DOI] [PubMed] [Google Scholar]
  • 9.Stocks T, Rapp K, Bjorge T, Manjer J, Ulmer H, Selmer R, Lukanova A, Johansen D, Concin H, Tretli S, Hallmans G, Jonsson H, et al. Blood glucose and risk of incident and fatal cancer in the metabolic syndrome and cancer project (me-can): analysis of six prospective cohorts. PLoS Med. 2009;6:e1000201. doi: 10.1371/journal.pmed.1000201. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Chodick G, Heymann AD, Rosenmann L, Green MS, Flash S, Porath A, Kokia E, Shalev V. Diabetes and risk of incident cancer: a large population-based cohort study in Israel. Cancer Causes Control. 2010;21:879–87. doi: 10.1007/s10552-010-9515-8. [DOI] [PubMed] [Google Scholar]
  • 11.Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM. Fasting serum glucose level and cancer risk in Korean men and women. JAMA. 2005;293:194–202. doi: 10.1001/jama.293.2.194. [DOI] [PubMed] [Google Scholar]
  • 12.Wideroff L, Gridley G, Mellemkjaer L, Chow WH, Linet M, Keehn S, Borch-Johnsen K, Olsen JH. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst. 1997;89:1360–5. doi: 10.1093/jnci/89.18.1360. [DOI] [PubMed] [Google Scholar]
  • 13.Khan M, Mori M, Fujino Y, Shibata A, Sakauchi F, Washio M, Tamakoshi A. Site-specific cancer risk due to diabetes mellitus history: evidence from the Japan Collaborative Cohort (JACC) Study. Asian Pac J Cancer Prev. 2006;7:253–9. [PubMed] [Google Scholar]
  • 14.Ragozzino M, Melton LJ, 3rd, Chu CP, Palumbo PJ. Subsequent cancer risk in the incidence cohort of Rochester, Minnesota, residents with diabetes mellitus. J Chronic Dis. 1982;35:13–9. doi: 10.1016/0021-9681(82)90025-x. [DOI] [PubMed] [Google Scholar]
  • 15.Ikeda F, Doi Y, Yonemoto K, Ninomiya T, Kubo M, Shikata K, Hata J, Tanizaki Y, Matsumoto T, Iida M, Kiyohara Y. Hyperglycemia increases risk of gastric cancer posed by Helicobacter pylori infection: a population-based cohort study. Gastroenterology. 2009;136:1234–41. doi: 10.1053/j.gastro.2008.12.045. [DOI] [PubMed] [Google Scholar]
  • 16.Rapp K, Schroeder J, Klenk J, Ulmer H, Concin H, Diem G, Oberaigner W, Weiland SK. Fasting blood glucose and cancer risk in a cohort of more than 140,000 adults in Austria. Diabetologia. 2006;49:945–52. doi: 10.1007/s00125-006-0207-6. [DOI] [PubMed] [Google Scholar]
  • 17.Cheng KK, Sharp L, McKinney PA, Logan RF, Chilvers CE, Cook-Mozaffari P, Ahmed A, Day NE. A case-control study of oesophageal adenocarcinoma in women: a preventable disease. Br J Cancer. 2000;83:127–32. doi: 10.1054/bjoc.2000.1121. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Neale RE, Doecke JD, Pandeya N, Sadeghi S, Green AC, Webb PM, Whiteman DC. Does type 2 diabetes influence the risk of oesophageal adenocarcinoma? Br J Cancer. 2009;100:795–8. doi: 10.1038/sj.bjc.6604908. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Rubenstein JH, Davis J, Marrero JA, Inadomi JM. Relationship between diabetes mellitus and adenocarcinoma of the oesophagus and gastric cardia. Aliment Pharmacol Ther. 2005;22:267–71. doi: 10.1111/j.1365-2036.2005.02544.x. [DOI] [PubMed] [Google Scholar]
  • 20.Reavis KM, Morris CD, Gopal DV, Hunter JG, Jobe BA. Laryngopharyngeal reflux symptoms better predict the presence of esophageal adenocarcinoma than typical gastroesophageal reflux symptoms. Ann Surg. 2004;239:849–56. doi: 10.1097/01.sla.0000128303.05898.ee. discussion 56–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.O’Mara BA, Byers T, Schoenfeld E. Diabetes mellitus and cancer risk: a multisite case-control study. J Chronic Dis. 1985;38:435–41. doi: 10.1016/0021-9681(85)90139-0. [DOI] [PubMed] [Google Scholar]
  • 22.Atchison EA, Gridley G, Carreon JD, Leitzmann MF, McGlynn KA. Risk of cancer in a large cohort of U.S. veterans with diabetes. Int J Cancer. 2011;128:635–43. doi: 10.1002/ijc.25362. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Lin S-W, Freedman ND, Hollenbeck A, Schatzkin A, Abnet CC. Prospective study of self-reported diabetes and risk of upper gastrointestinal cancers. Cancer Epidemiology Biomarkers & Prevention. 2011 doi: 10.1158/1055-9965.EPI-10-1244. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Wu AH, Wan P, Bernstein L. A multiethnic population-based study of smoking, alcohol and body size and risk of adenocarcinomas of the stomach and esophagus (United States) Cancer Causes Control. 2001;12:721–32. doi: 10.1023/a:1011290704728. [DOI] [PubMed] [Google Scholar]
  • 25.Wu AH, Tseng CC, Bernstein L. Hiatal hernia, reflux symptoms, body size, and risk of esophageal and gastric adenocarcinoma. Cancer. 2003;98:940–8. doi: 10.1002/cncr.11568. [DOI] [PubMed] [Google Scholar]
  • 26.Wu AH, Tseng CC, Hankin J, Bernstein L. Fiber intake and risk of adenocarcinomas of the esophagus and stomach. Cancer Causes Control. 2007;18:713–22. doi: 10.1007/s10552-007-9014-8. [DOI] [PubMed] [Google Scholar]
  • 27.Wu AH, Crabtree JE, Bernstein L, Hawtin P, Cockburn M, Tseng CC, Forman D. Role of Helicobacter pylori CagA+ strains and risk of adenocarcinoma of the stomach and esophagus. Int J Cancer. 2003;103:815–21. doi: 10.1002/ijc.10887. [DOI] [PubMed] [Google Scholar]
  • 28.Cockburn MG, Wu AH, Bernstein L. Etiologic clues from the similarity of histology-specific trends in esophageal and lung cancers. Cancer Causes Control. 2005;16:1065–74. doi: 10.1007/s10552-005-5382-0. [DOI] [PubMed] [Google Scholar]
  • 29.Vigen C, Bernstein L, Wu AH. Occupational physical activity and risk of adenocarcinomas of the esophagus and stomach. Int J Cancer. 2006;118:1004–9. doi: 10.1002/ijc.21419. [DOI] [PubMed] [Google Scholar]
  • 30.Duan L, Wu AH, Sullivan-Halley J, Bernstein L. Nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric adenocarcinomas in Los Angeles County. Cancer Epidemiol Biomarkers Prev. 2008;17:126–34. doi: 10.1158/1055-9965.EPI-07-0664. [DOI] [PubMed] [Google Scholar]
  • 31.Duan L, Wu AH, Sullivan-Halley J, Bernstein L. Passive smoking and risk of oesophageal and gastric adenocarcinomas. Br J Cancer. 2009;100:1483–5. doi: 10.1038/sj.bjc.6605023. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Duan L, Wu AH, Sullivan-Halley J, Bernstein L. Antacid drug use and risk of esophageal and gastric adenocarcinomas in Los Angeles County. Cancer Epidemiol Biomarkers Prev. 2009;18:526–33. doi: 10.1158/1055-9965.EPI-08-0764. [DOI] [PubMed] [Google Scholar]
  • 33.Berkey CS, Hoaglin DC, Mosteller F, Colditz GA. A random-effects regression model for meta-analysis. Statistics in Medicine. 1995;14:395–411. doi: 10.1002/sim.4780140406. [DOI] [PubMed] [Google Scholar]
  • 34.Thompson SG. Systematic Review: Why sources of heterogeneity in meta-analysis should be investigated. BMJ. 1994;309:1351–5. doi: 10.1136/bmj.309.6965.1351. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials. 1986;7:177–88. doi: 10.1016/0197-2456(86)90046-2. [DOI] [PubMed] [Google Scholar]
  • 36.Cochran WG. The Comparison of Percentages in Matched Samples. Biometrika. 1950;37:256–66. [PubMed] [Google Scholar]
  • 37.Centers for Disease Control and Prevention. Percentage of Civilian, Noninstitutionalized Population with Diagnosed Diabetes, by Age, United States, 1980–2008. 2011. [Google Scholar]
  • 38.Narayan KMV, Boyle JP, Thompson TJ, Gregg EW, Williamson DF. Effect of BMI on Lifetime Risk for Diabetes in the U. S Diabetes Care. 2007;30:1562–6. doi: 10.2337/dc06-2544. [DOI] [PubMed] [Google Scholar]
  • 39.Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4:579–91. doi: 10.1038/nrc1408. [DOI] [PubMed] [Google Scholar]
  • 40.Cronin-Fenton DP, Murray LJ, Whiteman DC, Cardwell C, Webb PM, Jordan SJ, Corley DA, Sharp L, Lagergren J. Reproductive and sex hormonal factors and oesophageal and gastric junction adenocarcinoma: a pooled analysis. Eur J Cancer. 2010;46:2067–76. doi: 10.1016/j.ejca.2010.03.032. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Mearin F, Malagelada JR. Gastroparesis and dyspepsia in patients with diabetes mellitus. Eur J Gastroenterol Hepatol. 1995;7:717–23. [PubMed] [Google Scholar]
  • 42.Stacher G, Lenglinger J, Bergmann H, Schneider C, Hoffmann M, Wölfl G, Stacher-Janotta G. Gastric emptying: a contributory factor in gastro-oesophageal reflux activity? Gut. 2000;47:661–6. doi: 10.1136/gut.47.5.661. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Boucher JL, Hurrell DG. Cardiovascular Disease and Diabetes. Diabetes Spectrum. 2008;21:154–5. [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supp Fig S1
Supp Table S1

RESOURCES